Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The primary purpose for this study is to support the hypothesis (pilot data) that the use of the CPM system reduces the rate of HF related events and the related healthcare cost. The study will also measure the impact on quality of care and patient satisfaction. In order to support the primary objective, the study will compare the outcomes and costs for patients using the CPM system against those who are not. This can either be done using institutions averages, if available, or through a control group.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Heart failure patients regardless of ejection fraction (HFpEF or HFrEF) with one or more of the following:

• NYHA Class III-IV

• NYHA Class II HF with one or more of the following:

• Chronic Kidney Disease (eGFR\<60 within the past 6 months)

• HF hospitalization (defined as HF listed as the major reason for hospitalization) within 9 months prior to screening visit and NT-proBNP \> 200 pg/ml for patients not in AF or \> 600 pg/m for patients in AF on screening ECG

• NT-proBNP \> 300 pg/ml for patients not in AF or \> 900 pg/ml for patients in AF on the screening visit ECG.

• Chronic obstructive pulmonary disease (COPD)

Locations
United States
Florida
Orlando Health
RECRUITING
Orlando
Contact Information
Primary
Emily Wycallis
emily.wycallis@analog.com
9784351644
Time Frame
Start Date: 2023-12-15
Estimated Completion Date: 2025-11-01
Participants
Target number of participants: 75
Treatments
Experimental: Study Group
The study group will use the CPM device daily for 6 months (beginning at visit 1 and ending at visit 2). The ADI triaging team will monitor the CPM device data and call the patient as indicated by the data. The ADI care team will then forward the device data and patient symptomology collected to the patient's care team where that team will device if intervention is necessary. The patient's care team will also have access to view device data at any time using the CPM website.
No_intervention: Control Group
The control group will not receive a device and will continue their normal standard of care.
Related Therapeutic Areas
Sponsors
Leads: Analog Device, Inc.
Collaborators: Orlando Health, Inc.

This content was sourced from clinicaltrials.gov